Definitive Contract 75A50324C00006
Award Date
5/1/24
Potential Completion Date
4/30/27
Potential Value
$125M
Awardee
Elusys Therapeutics Inc.
Ultimate Awardee
Nighthawk Biosciences, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the U.S. Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit organization and manufacturer of goods. The contract, valued at $44,971,900.00, is for "OTHER FUNCTIONS" and is a Firm Fixed Price Delivery Order with no set-aside designation. Elusys Therapeutics Inc. specializes in biomedical research and development, with a focus on advanced technology. The contract is related to the "ANTHIM" product, which...
The federal contract award HHSO100201000026C was issued by the Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit biomedical company, for advanced biomedical research and development. The $138,258,201.80 cost-plus-fixed-fee contract has an ultimate completion date of September 30, 2018. The contract is not designated as a set-aside. Elusys Therapeutics Inc. specializes in developing biomedical products and services, with a focus on advanced technology. The...
This is a firm fixed price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency under the Department of Health and Human Services (HHS), to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The $196,434,000 award is for the provision of anthrax antitoxins to treat inhalational anthrax, under the agency's medical countermeasures development and procurement program. The...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This federal contract award, valued at $43,027,525.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to Hawaii Biotech, Inc. (HBI), a biotechnology company focused on research and development of vaccines and therapeutics for infectious diseases. The contract is for the "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." It is a definitive, cost-plus-fixed-fee contract with a completion date of December 30, 2025....
<p>This is a $732,812.94 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Amplitude Therapeutics, Inc. on August 20, 2024. The contract is for the delivery of an AMPLITUDE THERAPEUTICS-A SPLIT-FORMULATED TRANS-AMPLIFYING RNA ENCODED ANTI-NEURAMINIDASE MONOCLONAL ANTIBODY and has an ultimate completion date of September 30, 2025. The contract does not utilize any set-aside designations.</p>
This is a $160,848,139.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Cangene Corporation for the development of anthrax therapeutics. The contract has an ultimate completion date of September 30, 2023 and utilizes a combination of pricing types. There is no set-aside designation for this award. The contract is for the research and development of medical countermeasures against anthrax, a critical component of the...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This is a $979,538.00 Firm Fixed Price Delivery Order contract awarded to Altimmune, Inc., a for-profit organization, by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. The contract, which was not set aside, is for the development of vaccine formulations effective against NIAID priority pathogens, evaluation of clone generation and stability, biodefense vaccine enhancement, and general biomedical research. Altimmune, Inc....
<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>